Current Trials

For more information about ongoing FibroGen clinical trials, please call (866) 266-0012 or email clinical contact.

FG-3019

FG-3019-028, Phase 1, Pancreatic Cancer
> Currently enrolling
FG-3019-049, Phase 2, Idiopathic Pulmonary Fibrosis
> Currently enrolling
FG-3019-801, Phase 2, Liver Fibrosis Due to Chronic Hepatitis B Infection
> Currently enrolling

FG-4592

FG-4592-040, Phase 2, Dialysis CKD Anemia
> Currently enrolling
FG-4592-041, Phase 2, Nondialysis CKD Anemia
> Currently enrolling
FG-4592-053, Phase 2, New Dialysis CKD Anemia
>Currently enrolling

May 3, 2011
FibroGen Reports Proof-of-Principle for Oral Anemia Therapy FG-4592 in Hemodialysis Patients Switched from Intravenous rhEPO in an Active-Controlled Randomized Phase 2 Study

March 17, 2011
FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF Prolyl Hydroxylase Inhibitor, for Treatment of Anemia in Chronic Kidney Disease

January 21, 2011
FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic Cancer

January 12, 2011
FibroGen Announces the Initiation of an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis